Noninvasive Prenatal Screening: Battleground In Diagnostics Innovation
Four companies have brought noninvasive prenatal testing to the market within the past two years. Its dramatic, rapid uptake has triggered a backlash among many geneticists, who fear the consequences of a poorly understood – and overhyped – technology.
You may also be interested in...
In our 11th annual analysis of Series A financings, we look at five sub-species of A round investors, their habits, habitats, and behaviors during 2014.
Concerns over patents, the anticipated regulatory oversight over complex tests, and reimbursement and evidence development characterized the continued upheaval in the diagnostics industry over the past year. However, genomics tools and technologies continue to be refined and introduced commercially, and companies with a sharp marketplace focus are showing they can still rise to the top.